Research programme: vaccines - Sinovac (Dalian) Vaccine Technology

Drug Profile

Research programme: vaccines - Sinovac (Dalian) Vaccine Technology

Alternative Names: Measles virus vaccine - Sinovac Biotech/Dalian Vaccine Technology; Rubella virus vaccine - Sinovac Biotech/Dalian Vaccine Technology

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinovac (Dalian) Vaccine Technology
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Measles; Rubella

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Measles(Prevention) in China (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rubella(Prevention) in China (Parenteral)
  • 05 Apr 2016 Sinovac enters into a technology transfer and supply agreement with GlaxoSmithkline to use GlaxoSmithkline's measles seeds to develop a measles vaccine and combination vaccines containing measles
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top